Zehua Lin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zehua Lin has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Aikebaier Tuohuti
Department of Otorhinolaryngology, Head and Neck Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China
6 shared publications - Lucheng Fang
Department of Otorhinolaryngology, Head and Neck Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
6 shared publications - Qiang Xie
Department of Otorhinolaryngology, Head and Neck Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China
6 shared publications - Qiuyang Fu
Otolaryngology Department of The Second Affiliated Hospital, School of Medicine, The Chinese University of Hong Kong, Shenzhen, China
6 shared publications - Sa Wu
Clin Lab, BGI Genomics, Wuhan, China
6 shared publications - Weisong Cai
Department of Otorhinolaryngology, Head and Neck Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China
6 shared publications
Latest Publications
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from MTHFD2-Mediated Ubiquitination and Degradation of FOXO1 Promote Tongue Squamous Cell Carcinoma Progression
Supplementary Figure S2. The MTHFD2 inhibitor DS18561882 impairs proliferation and migration of TSCC cells.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from MTHFD2-Mediated Ubiquitination and Degradation of FOXO1 Promote Tongue Squamous Cell Carcinoma Progression
Supplementary Figure S2. The MTHFD2 inhibitor DS18561882 impairs proliferation and migration of TSCC cells.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from MTHFD2-Mediated Ubiquitination and Degradation of FOXO1 Promote Tongue Squamous Cell Carcinoma Progression
The list of TSCC patient cases from the TCGA-HNSC project used for the Kaplan-Meier survival analysis is provided in Supplementary File Table 2
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from MTHFD2-Mediated Ubiquitination and Degradation of FOXO1 Promote Tongue Squamous Cell Carcinoma Progression
The list of TSCC patient cases from the TCGA-HNSC project used for the Kaplan-Meier survival analysis is provided in Supplementary File Table 2
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Data from MTHFD2-Mediated Ubiquitination and Degradation of FOXO1 Promote Tongue Squamous Cell Carcinoma Progression
Methylenetetrahydrofolate dehydrogenase 2 (MTHFD2), a pivotal enzyme in one-carbon metabolism, is significantly overexpressed in tongue squamous cell carcinoma (TSCC) and correlates with poor patient prognosis. Functional studies demonstrate that MTHFD2 drives TSCC proliferation and migration in vitro and in vivo, whereas its inhibition suppresses tumor progression. Mechanistically, MTHFD2 orchestrates a dual posttranslational modification cascade: Through its enzymatic activity, it simultaneously induces forkhead box O1 (FOXO1) hypermethylation and ubiquitination, ultimately triggering ubiquitin–proteasome degradation of this tumor suppressor. This methylation-primed degradation axis is clinically validated by the inverse MTHFD2-high/FOXO1-low expression pattern in TSCC specimens, which predicts adverse outcomes. Critically, pharmacologic inhibition of MTHFD2 (e.g., DS18561882) blocks FOXO1 degradation, establishing the MTHFD2–FOXO1 axis as a promising therapeutic target for TSCC through its novel metabolic–epigenetic regulatory mechanism.Implications:This study identifies the MTHFD2–FOXO1 axis as a druggable metabolic–epigenetic pathway in TSCC, providing both a prognostic marker and a therapeutic target.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from MTHFD2-Mediated Ubiquitination and Degradation of FOXO1 Promote Tongue Squamous Cell Carcinoma Progression
Methylenetetrahydrofolate dehydrogenase 2 (MTHFD2), a pivotal enzyme in one-carbon metabolism, is significantly overexpressed in tongue squamous cell carcinoma (TSCC) and correlates with poor patient prognosis. Functional studies demonstrate that MTHFD2 drives TSCC proliferation and migration in vitro and in vivo, whereas its inhibition suppresses tumor progression. Mechanistically, MTHFD2 orchestrates a dual posttranslational modification cascade: Through its enzymatic activity, it simultaneously induces forkhead box O1 (FOXO1) hypermethylation and ubiquitination, ultimately triggering ubiquitin–proteasome degradation of this tumor suppressor. This methylation-primed degradation axis is clinically validated by the inverse MTHFD2-high/FOXO1-low expression pattern in TSCC specimens, which predicts adverse outcomes. Critically, pharmacologic inhibition of MTHFD2 (e.g., DS18561882) blocks FOXO1 degradation, establishing the MTHFD2–FOXO1 axis as a promising therapeutic target for TSCC through its novel metabolic–epigenetic regulatory mechanism.Implications:This study identifies the MTHFD2–FOXO1 axis as a druggable metabolic–epigenetic pathway in TSCC, providing both a prognostic marker and a therapeutic target.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from MTHFD2-Mediated Ubiquitination and Degradation of FOXO1 Promote Tongue Squamous Cell Carcinoma Progression
Supplementary Figures S1. Prognostic value of gene expression levels in TSCC patients.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from MTHFD2-Mediated Ubiquitination and Degradation of FOXO1 Promote Tongue Squamous Cell Carcinoma Progression
Supplementary Figures S1. Prognostic value of gene expression levels in TSCC patients.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from MTHFD2-Mediated Ubiquitination and Degradation of FOXO1 Promote Tongue Squamous Cell Carcinoma Progression
A complete list of experimental reagents and resources is included in Supplementary Table 1.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from MTHFD2-Mediated Ubiquitination and Degradation of FOXO1 Promote Tongue Squamous Cell Carcinoma Progression
A complete list of experimental reagents and resources is included in Supplementary Table 1.
- 19 November 2025
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 24 (4) , 270-282
MTHFD2-Mediated Ubiquitination and Degradation of FOXO1 Promote Tongue Squamous Cell Carcinoma Progression
Methylenetetrahydrofolate dehydrogenase 2 (MTHFD2), a pivotal enzyme in one-carbon metabolism, is significantly overexpressed in tongue squamous cell carcinoma (TSCC) and correlates with poor patient prognosis. Functional studies demonstrate that MTHFD2 drives TSCC proliferation and migration in vitro and in vivo, whereas its inhibition suppresses tumor progression. Mechanistically, MTHFD2 orchestrates a dual posttranslational modification cascade: Through its enzymatic activity, it simultaneously induces forkhead box O1 (FOXO1) hypermethylation and ubiquitination, ultimately triggering ubiquitin–proteasome degradation of this tumor suppressor. This methylation-primed degradation axis is clinically validated by the inverse MTHFD2-high/FOXO1-low expression pattern in TSCC specimens, which predicts adverse outcomes. Critically, pharmacologic inhibition of MTHFD2 (e.g., DS18561882) blocks FOXO1 degradation, establishing the MTHFD2–FOXO1 axis as a promising therapeutic target for TSCC through its novel metabolic–epigenetic regulatory mechanism. Implications: This study identifies the MTHFD2–FOXO1 axis as a druggable metabolic–epigenetic pathway in TSCC, providing both a prognostic marker and a therapeutic target.
- 19 November 2025
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 24 (4) , 270-282
MTHFD2-Mediated Ubiquitination and Degradation of FOXO1 Promote Tongue Squamous Cell Carcinoma Progression
Methylenetetrahydrofolate dehydrogenase 2 (MTHFD2), a pivotal enzyme in one-carbon metabolism, is significantly overexpressed in tongue squamous cell carcinoma (TSCC) and correlates with poor patient prognosis. Functional studies demonstrate that MTHFD2 drives TSCC proliferation and migration in vitro and in vivo, whereas its inhibition suppresses tumor progression. Mechanistically, MTHFD2 orchestrates a dual posttranslational modification cascade: Through its enzymatic activity, it simultaneously induces forkhead box O1 (FOXO1) hypermethylation and ubiquitination, ultimately triggering ubiquitin–proteasome degradation of this tumor suppressor. This methylation-primed degradation axis is clinically validated by the inverse MTHFD2-high/FOXO1-low expression pattern in TSCC specimens, which predicts adverse outcomes. Critically, pharmacologic inhibition of MTHFD2 (e.g., DS18561882) blocks FOXO1 degradation, establishing the MTHFD2–FOXO1 axis as a promising therapeutic target for TSCC through its novel metabolic–epigenetic regulatory mechanism. Implications: This study identifies the MTHFD2–FOXO1 axis as a druggable metabolic–epigenetic pathway in TSCC, providing both a prognostic marker and a therapeutic target.